CR-350

N/A

Report date: 2022/01/05 15:24:33
NME

Base Information

Drug NameCR-350
Drug Alias NameCR-350
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase alpha inhibitorsProto-oncogene proteins c-akt inhibitors
TargetsSerine/threonine-protein kinase mTORPhosphatidylinositol 3 kinase alpha
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Crmed Science Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Crmed Science Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A